Benjamin Stone - 20 Apr 2026 Form 3 Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)

Reporting relationship
Chief Business Officer
Issuer ticker
TRAX
Reported as of
20 Apr 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
22 Apr 2026, 16:19:17 UTC
Next SEC filing
14 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

Benjamin Stone filed Form 3 for First Tracks Biotherapeutics, Inc. (TRAX) on 22 Apr 2026.

Key facts

  • This page summarizes Benjamin Stone's Form 3 filing for First Tracks Biotherapeutics, Inc. (TRAX).
  • 0 reported transactions and 11 derivative rows are listed below.
  • Accepted by SEC: 22 Apr 2026, 16:19.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002128786 Primary reporting owner

STONE BENJAMIN

Relationship
Chief Business Officer
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Signature date
22 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRAX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
17,262
Date
20 Apr 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAX holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
43,750
Exercise price
$5.80
Footnotes
F2
TRAX holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
48,300
Exercise price
$6.22
Footnotes
F3
TRAX holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
112,790
Exercise price
$5.67
Footnotes
F4
TRAX holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
92,500
Exercise price
$3.97
Footnotes
F5
TRAX holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
36,700
Exercise price
$11.75
Footnotes
F6
TRAX holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,100
Exercise price
$7.66
Footnotes
F7
TRAX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,425
Exercise price
Footnotes
F8, F9
TRAX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,605
Exercise price
Footnotes
F9, F10
TRAX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
24,337
Exercise price
Footnotes
F9, F11
TRAX holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
27,100
Exercise price
Footnotes
F9, F12
TRAX holding Derivative

Performance Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
20 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,000
Exercise price
Footnotes
F13, F14
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 14 footnotes

Footnote F1

Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").

Footnote F2

The stock option vests as to 25% of the total shares on June 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F3

The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F4

The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F5

The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F6

The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F7

This stock option is fully vested.

Footnote F8

The restricted stock units ("RSUs") vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F9

Each RSU represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.

Footnote F10

The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F11

The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F12

The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F13

Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 50% of the total number of shares subject to the PSU shall vest each on July 1, 2025 and July 1, 2026 ("Vestings"), upon Performance Metrics achieved. If such Vestings do not occur, 100% of the PSUs shall fully vest on July 1, 2028. subject to the Reporting Person' service to the Issue on each vesting date.

Footnote F14

Each PSU represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.

SEC remarks

On April 20, 2026, in connection with the AnaptysBio spin-off of First Tracks (the "Spin-Off"), AnaptysBio distributed all outstanding equity awards of First Tracks to the Reporting Person previously granted to the reporting person from AnaptysBio, which modification is intended to preserve the underlying value of the outstanding equity awards. The distributed equity awards remain subject to the same vesting conditions as those under the original equity awards.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .